急性心筋梗塞市場 - 市場の洞察、疫学、市場予測：2034年

主要7ヶ国における急性心筋梗塞（AMI）の市場規模は2022年に約16億米ドルなりました。今後、予測期間中に大幅なCAGRで増加すると予測されます。主要7ヶ国諸国の中でAMIの市場規模が最も大きいのは米国と予想されます。2022年、米国の市場規模は12億米ドルでした。主要7ヶ国諸国の中で、2022年の市場規模が最も小さいのはスペインで、2,500万米ドルでした。

AMIは病理学的には長時間の虚血別心筋細胞死と定義されます。細胞グリコーゲンの減少、筋原線維の弛緩とサルコレメンタルの破壊が最初の超微細構造変化であり、虚血発症後10～15分という早い時期に認められます。

AMIに伴う症状としては、胸痛があり、最初は締め付けられるような感覚や圧迫感として現れます。痛みは左腕に放散することが最も多いが、下顎、頸部、右腕、背部、上腹部に放散することもあります。胸痛は発汗、吐き気や嘔吐、失神を伴うこともあります。

過去20年間にAMIの診断に心臓バイオマーカーが使用されるようになり、心筋傷害やAMIの定義に使用される臨床検査のカットオフ値が変化していることは、AMIの動向に関する多くの研究において最も明白な複雑要因です。

当レポートでは、主要7ヶ国における急性心筋梗塞市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 AMI市場概要

• 2020年の市場シェア分布（%）、治療法別
• 2034年の市場シェア分布（%）、治療法別

第4章 エグゼクティブサマリー

第5章 疫学と市場予測調査手法

第6章 主要な出来事

第7章 疾患の背景と概要

• イントロダクション
• 危険因子
• 病態生理学
• 心筋梗塞の臨床分類
• 診断
• バイオマーカー
• 以前のMIの定義
• WHOのMIの定義と診断基準

第8章 治療と管理

• 抗血小板剤
• 抗凝固剤

第9章 MIに対するガイドラインと推奨事項

第10章 主要7ヶ国におけるAMIの疫学と患者数

• 主な調査結果
• 仮定と根拠
• 主要7ヶ国におけるAMIの総事件数
• 米国
• EU4ヶ国と英国
• 日本

第11章 患者動向

第12章 上市済み薬剤

第13章 その他の市場資産

第14章 新しい治療法

第15章 急性心筋梗塞（AMI）：主要7ヶ国市場分析

• 主な調査結果
• 市場の見通し
• コンジョイント分析
• 主要な市場予測の前提条件
• 主要7ヶ国におけるAMIの総市場規模
• 米国の市場規模
• EU4ヶ国と英国の市場規模
• 日本の市場規模

第16章 アンメットニーズ

第17章 SWOT分析

第18章 KOLの見解

第19章 市場アクセスと償還

• 米国
• EU4ヶ国と英国
• 日本
• AMIにおける償還シナリオとHTAの主要な決定

第20章 付録

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

List of Tables

• Table 1: Summary of AMI Market, and Epidemiology (2020-2034)
• Table 2: Comparison of Anticoagulants Used to Treat Acute Coronary Syndrome
• Table 3: Recommendations for the management of Stage B: Preventing the syndrome of clinical HF in patients with Pre-HF
• Table 4: Benefits and risks of early invasive treatment (coronary angiography with PCI if needed) compared with conservative management for people with unstable angina or NSTEMI
• Table 5: Total Incident Cases of AMI in the 7MM in thousands (2020-2034)
• Table 6: Total Incident Cases of AMI in the United States (2020-2034)
• Table 7: Type-specific Incidence of MI in the United States (2020-2034)
• Table 8: Gender-specific Incidence of AMI in the United States (2020-2034)
• Table 9: Total Incident Cases of AMI in EU4 and the UK (2020-2034)
• Table 10: Type-specific Incidence of AMI in EU4 and the UK (2020-2034)
• Table 11: Gender-specific Incidence of AMI in EU4 and the UK (2020-2034)
• Table 12: Total Incident Cases of AMI in Japan (2020-2034)
• Table 13: Type-specific Incidence of AMI in Japan (2020-2034)
• Table 14: Gender-specific Incidence of MI in Japan (2020-2034)
• Table 15: Comparison of Marketed Drugs
• Table 16: REPATHA (evolocumab) Clinical Trial Description, 2023
• Table 17: ZONTIVITY, Clinical Trial Description, 2023
• Table 18: PRALUENT, Clinical Trial Description, 2023
• Table 19: Comparison of Other Assets
• Table 20: Comparison of Emerging Drugs
• Table 21: JARDIANCE, Clinical Trial Description, 2023
• Table 22: Selatogrel, Clinical Trial Description, 2023
• Table 23: Dutogliptin, Clinical Trial Description, 2023
• Table 24: Milvexian, Clinical Trial Description, 2023
• Table 25: FARXIGA/FORXIGA, Clinical Trial Description, 2023
• Table 26: FDY-5301, Clinical Trial Description, 2023
• Table 27: CSL112, Clinical Trial Description, 2023
• Table 28: Olpasiran, Clinical Trial Description, 2023
• Table 29: Key Market Forecast Assumption of AMI in the US
• Table 30: Key Market Forecast Assumption of AMI in EU4 and the UK
• Table 31: Key Market Forecast Assumption of AMI in Japan
• Table 32: Total Market Size of AMI in the 7MM, in USD million (2020-2034)
• Table 33: Total Market Size of AMI in the US, in USD million (2020-2034)
• Table 34: Market Size of AMI by Therapies in the US, in USD million (2020-2034)
• Table 35: Total Market Size of AMI in EU4 and the UK, in USD million (2020-2034)
• Table 36: Market Size of AMI by Therapies in EU4 and the UK, in USD million (2020-2034)
• Table 37: Total Market Size of AMI in Japan, in USD million (2020-2034)
• Table 38: Market Size of AMI by Therapies in Japan, in USD million (2020-2034)
• Table 39: Country-specific PCSK9i Reimbursement and Treatment Initiation Requirements for use Post-MI

List of Figures

• Figure 1: Framework for Type 2 Myocardial Infarction Considering the Clinical Context and Pathophysiological Mechanisms Attributable to Acute Myocardial Ischemia
• Figure 2: A Model for Interpreting Myocardial Injury
• Figure 3: Diagnostic Algorithm for Myocardial Infarction With Non-obstructive Coronary Arteries Using a Traffic Light
• Figure 4: Common complications following acute myocardial infarction and their approximate timing
• Figure 5: Total Incident Cases of AMI in the 7MM (2020-2034)
• Figure 6: Total Incident Cases of AMI in the United States (2020-2034)
• Figure 7: Type-specific Incidence of AMI in the United States (2020-2034)
• Figure 8: Gender-specific Incidence of AMI in the United States (2020-2034)
• Figure 9: Total Incident Cases of AMI in EU4 and the UK (2020-2034)
• Figure 10: Type-specific Incidence of AMI in EU4 and the UK (2020-2034)
• Figure 11: Gender-specific Incidence of AMI in EU4 and the UK (2020-2034)
• Figure 12: Total Incident Cases of AMI in Japan (2020-2034)
• Figure 13: Type-specific Incidence of AMI in Japan (2020-2034)
• Figure 14: Gender-specific Incidence of AMI in Japan (2020-2034)
• Figure 15: Total Market Size of AMI in the 7MM (2020-2034)
• Figure 16: Total Market Size of AMI in the US (2020-2034)
• Figure 17: Market Size of AMI by Therapies in the US (2020-2034)
• Figure 18: Total Market Size of AMI in EU4 and the UK (2020-2034)
• Figure 19: Market Size of AMI by Therapies in EU4 and the UK (2020-2034)
• Figure 20: Total Market Size of AMI in Japan (2020-2034)
• Figure 21: Market Size of AMI by Therapies in Japan (2020-2034)
• Figure 22: Health Technology Assessment
• Figure 23: Reimbursement Process in Germany
• Figure 24: Reimbursement Process in France
• Figure 25: Reimbursement Process in Italy
• Figure 26: Reimbursement Process in Spain
• Figure 27: Reimbursement Process in the United Kingdom
• Figure 28: Reimbursement Process in Japan

Key Highlights:

• AMI is defined pathologically as myocardial cell death due to prolonged ischemia. Diminished cellular glycogen, and relaxed myofibrils and sarcolemmal disruption, are the first ultrastructural changes and are seen as early as 10-15 minutes after the onset of ischemia.
• Symptoms associated to AMI includes chest pain that may appear as a sensation of tightness or pressure initially. Pain radiates most often to the left arm, but may also radiate to the lower jaw, neck, right arm, back, and upper abdomen. Chest pain may be accompanied by sweating, nausea or vomiting, and fainting.
• The increasing use of cardiac biomarkers for diagnosing AMI during the past two decades and the changing cutoff levels for the laboratory tests used to define myocardial injury or AMI are the most apparent complicating factors in many studies of AMI trends.
• The use of biomarkers has likely improved the ascertainment of MI over time, which would have the dual effects of potentially masking actual reductions in disease incidence because of primary prevention efforts and leading to false improvements in MI-related case fatality attributable to the inclusion of smaller infarctions that previously would have been clinically unrecognized.
• The total incident cases of AMI in the 7MM were ~1,500,000 in 2022 out of which the highest incident cases of this disease were in the United States.
• Among the total AMI incident cases, NSTEMI type were estimated to be more than STEMI type, with NSTEMI accounting for approximately 500,000 cases in the United States in 2022.
• Current treatment market has been segmented into the following therapeutic classes namely: Antiplatelet agents, Anticoagulants, Vasodilators, Beta Blockers, Lipid-lowering drugs, Angiotensin-converting Enzyme Inhibitors (ACE), Angiotensin-II receptor Blockers (ARBs), and Calcium channel blockers.
• The dynamics of AMI market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world.
• The market size of AMI in the 7MM is estimated to be around USD 1,600 million in 2022 and is expected to increase with a significant CAGR during the forecast period.
• Among the 7MM countries, the United States is expected to account for the largest market size of AMI among the 7MM countries. Accounting for approximately 75% of the overall market in 2022.
• Among EU4 countries and the UK, Germany is expected to generate the largest revenue during the forecast period.
• Key players in the therapeutic market of AMI at the global level are AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen, Novartis, etc. Launch of emerging therapy, such as CSL112, selatogrel, and olpasiran (AMG860) will significantly impact the AMI market during the forecast period (2024-2034).
• Among the potential emerging therapies that can significantly change the market landscape during the forecast period, it is estimated that CSL112, a novel apolipoprotein A-I infusion therapy is estimated to have the highest revenue after its launch, which is estimated to be before 2025.
• Selatogrel, a P2Y12 receptor antagonist, developed by Idorsia, has also shown very promising safety and efficacy results. The US FDA has granted the drug fast-track designation and a Special Protocol Assessment (SPA) to this drug. Selatogrel protects the heart muscle at a crucial time between symptom onset and when the patient receives medical attention.

Report Summary

• The detailed report provides significant knowledge about epidemiological segments, including the historical and forecasted patient pool data, thus providing a thorough picture of anticipated future development in incident pool and treatment guidelines. It gives deep insights into various areas, allowing for a complete examination of the subject.
• The report also includes an all-inclusive account of current management techniques and emerging therapies and elaborative profiles of late-stage (Phase III and Phase II) and prominent therapies that would impact the current treatment landscape and result in an overall market shift. The therapy profiles include a detailed assessment of the current and emerging therapies, information regarding the approval-based and ongoing trials, and a thorough drug description.
• The report also encompasses a comprehensive analysis of the AMI market, providing an in-depth examination of its historical and projected market size (2020-2034). It also includes the market share of therapies, detailed assumptions, and the underlying rationale for our methodology. The report also includes drug outreach coverage in the 7MM region.
• The report includes qualitative as well as quantitative insights that provide an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, which gives an overview of the patient landscape commencing from detection of the disease to treatment being administered to the patients, with the treatment preferences that help shape and drive the 7MM AMI market.

Market

Various key players are currently investigating their drugs for AMI, such as AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Janssen Pharmaceutical and Bristol-Myers Squibb, Recardio, and others. The details of the country and therapy-wise market size have been provided below.

• In the 7MM region, the United States captured the largest market size in 2022. In 2022, the market size of the United States was ~USD 1,200 million
• Among the 7MM countries, Spain accounted for the smallest market size in 2022, ~USD 25 million.
• Among the emerging therapies that are estimated to be launched in our forecast period, CSL112 is estimated to have the highest revenue by 2034.

AMI Drug Chapters

The AMI report's drugs section includes an in-depth examination of marketed drugs and late-stage pipeline therapeutics (Phase III and Phase II) for AMI.

The drug chapters section contains useful information on various aspects of AMI clinical trials, including specific details such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. It also includes the most recent news updates and press releases on drugs that treat AMI.

Marketed Therapies

TNKASE (tenecteplase): Genentech

TNKASE (tenecteplase) is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line. Tenecteplase is a variant of the native tissue-type plasminogen activator (tPA) molecule with 14-fold greater fibrin specificity than alteplase, a longer half-life, slower plasma clearance, and 80-fold greater resistance to inhibition by plasminogen activator inhibitor type 1. Its half-life of ~18 min allows single-bolus administration.

REPATHA (evolocumab): Amgen

REPATHA (evolocumab) is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Over the last decade, inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising target to reduce residual cardiovascular disease risk. PCSK9 is a protein that binds to low-density lipoprotein (LDL) receptors (LDLR) to promote their degradation. Monoclonal antibodies inhibit PCSK9 and thus prevent LDLR degradation.

ZONTIVITY (vorapaxar): Merck

ZONTIVITY (vorapaxar) is the first and only therapy shown to inhibit the protease-activated receptor-1 (PAR-1), the primary receptor for thrombin, which is considered the most potent activator of platelets. The PAR-1 pathway participates in the formation of blood clots through the activation and aggregation of platelets. ZONTIVITY addresses this additional pathway not targeted by aspirin or P2Y12 inhibitors, like clopidogrel.

Note: Detailed assessment will be provided in the final report of AMI.

Emerging Therapies

JARDIANCE (empagliflozin): Boehringer Ingelheim/Eli Lilly and Company

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporter primarily responsible for glucose re-absorption in the kidney. It is marketed under JARDIANCE and is the first type 2 diabetes medicine to include cardiovascular death risk reduction data on the label in several countries. Empagliflozin lowers blood glucose levels by preventing glucose re-absorption in the kidneys and increasing the amount of glucose excreted in the urine. Right now it is in Phase III clinical trials and FDA granted the Fast Track Designation.

Selatogrel: Idorsia Pharmaceuticals

Selatogrel is a potent, highly selective, fast-acting, and reversible P2Y12 receptor antagonist being developed for treating AMI in patients at high risk of recurrent AMI. It is self-administered subcutaneously via a drug delivery device (autoinjector) upon the occurrence of symptoms suggestive of an AMI. In 2020, the FDA designated the investigation of Selatogrel for treating a suspected AMI in adult patients with a history of AMI as a fast-track development program.

CSL112: CSL Behring

CSL112, apolipoprotein A-I (human), is being developed by CSL Behring, currently in an ongoing Phase III clinical development trial. It is a novel formulation of plasma-derived apoA-I, the primary functional component of HDL. It is reconstituted to form HDL-like particles suitable for IV infusion. Studies have shown that infusion of CSL112 rapidly enhances cholesterol efflux capacity. CSL112 may offer a new approach for rapidly stabilizing atherosclerotic plaque lesions and is being developed to reduce the risk of early cardiovascular events in AMI patients.

Note: Detailed assessment will be provided in the final report of AMI.

AMI Market Outlook

Acute Myocardial Infarction (AMI), commonly referred to as a heart attack, is a medical emergency that occurs when there is a sudden interruption in the blood supply to a portion of the heart muscle. This interruption is typically caused by a blockage in one of the coronary arteries, which are responsible for supplying oxygen and nutrients to the heart muscle

AMI carries a common manifestation of CVD in the elderly with an increased risk of mortality, morbidity, and excess costs. Currently, there are multiple effective management options following myocardial infarction, and guidelines recommend lifelong pharmaceutical prevention with beta-blockers, ACE inhibitors or angiotensin II receptor blockers, acetylsalicylic acid, and statins if not contraindicated.

The market size of AMI in the 7MM was estimated to be around USD 1,600 million in 2022 and is expected to increase during the forecast period [2024-2034]. The United States is expected to account for the largest market size of AMI among the 7MM countries, during the study period [2020-2034]. Among the EU4 countries and the UK, Germany is expected to generate the largest revenue during the forecast period.

The current market has been segmented accordingly into different commonly used therapeutic classes based on the prevailing treatment pattern across the 7MM, which present itself with minor variations in the overall prescription pattern. Antiplatelet agents, Anticoagulants, Vasodilators, Beta Blockers, Lipid-lowering drugs, Angiotensin-converting Enzyme Inhibitors (ACE), Angiotensin-II receptor Blockers (ARBs), and Calcium channel blockers are the major classes that have been covered in the forecast model.

Note: Detailed assessment will be provided in the final report of AMI.

AMI Understanding and Treatment

AMI Overview

Acute myocardial infarction (AMI) is myocardial necrosis resulting from acute obstruction of a coronary artery. Symptoms include chest discomfort with or without dyspnea, nausea, and/or diaphoresis. Diagnosis is by electrocardiography (ECG) and the presence or absence of serologic markers. Treatment is antiplatelet drugs, anticoagulants, nitrates, beta-blockers, statins, and reperfusion therapy. For ST-segment-elevation myocardial infarction, emergency reperfusion is via fibrinolytic drugs, percutaneous intervention, or, occasionally, coronary artery bypass graft surgery. For non-ST-segment-elevation myocardial infarction, reperfusion is via percutaneous intervention or coronary artery bypass graft surgery

AMI is one of the leading causes of death in the developed world. AMI can be divided into two categories, non-ST-segment elevation MI (NSTEMI) and ST-segment elevation MI (STEMI). Unstable angina is similar to NSTEMI. However, cardiac markers are not elevated.

A detailed overview will be provided in the final report.

AMI Diagnosis

The initial evaluation of a patient with a suspected AMI should include a focused clinical history, physical examination, electrocardiography, cardiac markers, and a chest radiograph. An ECG is especially useful for distinguishing between an NSTEMI and a STEMI. Serum biomarkers of myocardial necrosis include cardiac-specific troponins T and I, MB isoforms of creatine (CK-MB), creatine kinase (CK), and myoglobin. Myocardial injury is diagnosed as wall motion abnormalities on echocardiography. An echocardiogram, however, cannot distinguish between an acute STEMI from an old myocardial scar or severe acute ischemia, but ease and safety make it useful as a screening tool to aid management decisions. There are several other causes of chest pain that can masquerade as a myocardial infarction. Most notable include acute pericarditis, pulmonary embolism, acute aortic dissection, costochondritis, and gastroesophageal reflux disease.

Further details related to diagnosis are provided in the report.

AMI Treatment

The goals of initial treatment of an MI are relief of pain, immediate identification of ST changes via 12-lead EKG, initiation of reperfusion (if the patient is a candidate), and assessment and treatment of hemodynamic abnormalities. Pain relief is best achieved with oxygen, nitroglycerin, and morphine sulfate. Patients with ST-segment elevation or a new LBBB with symptoms for 12 h or less are candidates for reperfusion therapy. Further treatment of an MI may be separated into two pathways depending on whether or not the patient has a STEMI or an NSTEMI.

Further details related to treatment and management are provided in the report...

AMI Epidemiology

The AMI epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of AMI, Type-specific Incidence of AMI, and Gender-specific Incidence of AMI covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034

• The total incident cases of AMI in the United States is estimated to be ~820,000 in 2022. The cases are expected to increase by 2034.
• There were ~44,000 cases of STEMI and ~34,000 cases of NSTEMI in Japan in 2022.
• In EU4 and the UK, the incident cases of AMI were ~415,000 cases in males and ~184,000 cases in females in 2022.

Further details related to epidemiology will be provided in the report.

KOL Views

In order to stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

We have reached out to industry experts to gather insights on various aspects of AMI, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.

Our team of analysts at DelveInsight connected with more than 10 KOLs across the 7 Major Markets (7MM). We contacted institutions such as Stanford Medicine, University of Barcelona and others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the AMI market, which will assist our clients in analyzing the overall epidemiology and market scenario.

Qualitative Analysis

We conduct qualitative and market intelligence analysis employing various methods, including SWOT analysis and Conjoint Analysis. Strengths, weaknesses, opportunities, and threats in disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are described in the SWOT analysis. These recommendations are based on the Analyst's evaluation of the patient burden, cost analysis, and the current and emerging therapy landscape. Conjoint Analysis compares the effectiveness and safety of numerous approved and emergent drugs depending on key criteria such as frequency of administration, designation, route of administration, and order of entry. To assess the success of therapy, several factors are evaluated.

Furthermore, the drug's safety is analyzed, in which acceptability, tolerability, and adverse events are closely monitored, and it establishes a firm grasp of the side effects of the drugs used in the trials. Furthermore, for each therapy, the rating is based on the route of administration, sequence of entrance and designation, chance of success, and addressable patient pool. These characteristics determine the ultimate weightage score and ranking of developing therapeutics.

Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

AMI Insights

• Patient Population
• Therapeutic Approaches
• Market size of each therapy
• AMI Market Size and Trends
• Existing Market Opportunity

AMI Report Key Strengths

• Eleven-year Forecast
• The 7MM Coverage
• AMI Epidemiology Segmentation (Segmented by incident cases, type, and gender-specific Cases)
• Key Cross Competition evaluating the marketed as well as emerging therapies

AMI Report Assessment

• Current Treatment and Management Practices
• Unmet Needs
• Market Attractiveness
• Qualitative Analysis (SWOT, Conjoint Analysis)

Key Questions:

• Would there be any changes observed in the current treatment approach?
• Will there be any improvements in AMI management recommendations?
• Would research and development advances pave the way for future tests and therapies for AMI?
• Would the innovations in diagnostic tests of AMI space experience a significant impact and lead to a positive shift in the treatment landscape of AMI?
• What kind of uptake will the new therapies witness in the coming years in AMI patients?

Table of Contents

1. Key Insights

2. Report Introduction

3. AMI Market Overview at a Glance

• 3.1. Market Share Distribution by Therapies (%) in 2020
• 3.2. Market Share Distribution by Therapies (%) in 2034

4. Executive Summary

5. Epidemiology and Market Forecast Methodology

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Risk Factors
• 7.3. Pathophysiology
• 7.4. Clinical Classification of Myocardial Infarction
  • 7.4.1. Type 1
  • 7.4.2. Type 2
  • 7.4.3. Type 2 and myocardial injury
  • 7.4.4. Type 3
  • 7.4.5. Type 4a: Myocardial Infarction Associated With Percutaneous Coronary Intervention
  • 7.4.6. Type 4b: Stent/Scaffold Thrombosis Associated With Percutaneous Coronary Intervention
  • 7.4.7. Type 4c: Restenosis Associated With Percutaneous Coronary Intervention
  • 7.4.8. Type 5: Myocardial Infarction Associated With Coronary Artery Bypass Grafting
• 7.5. Diagnosis
• 7.6. Biomarkers
  • 7.6.1. Biomarkers Originated From Myocardial Tissues
  • 7.6.2. Biomarkers Induced by MI Incidence
  • 7.6.3. Biomarkers Preexisted Before MI Occurred
• 7.7. Definition of a Prior MI
  • 7.7.1. Recurrent MI
  • 7.7.2. Reinfarction
  • 7.7.3. Peri-procedural MI
• 7.8. WHO definition and diagnostic criteria of MI
  • 7.8.1. Category A definition and Diagnostic Criteria of MI
  • 7.8.2. Category B definition and diagnostic criteria of MI if the requirements for diagnostic tests in Category A (above) Have Not Been Met
  • 7.8.3. Category C definition and diagnostic criteria of probable MI
  • 7.8.4. Fourth Universal Definition of Myocardial Infarction

8. Treatment and Management

• 8.1. Antiplatelet agents
• 8.2. Anticoagulant agents

9. Guidelines and Recommendations for MI

• 9.1. AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines: 2022
• 9.2. NICE Guidelines for Acute coronary syndromes: 2020
• 9.3. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation: 2017
• 9.4. Evidenced-based Recommendations from the Guidelines
• 9.5. ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

10. Epidemiology and Patient Population of AMI in the 7MM

• 10.1. Key Findings
• 10.2. Assumptions and Rationale
• 10.3. Total Incident Cases of AMI in the 7MM
• 10.4. The United States
  • 10.4.1. Total Incident Cases of AMI in the United States
  • 10.4.2. Type-specific Incident Cases of AMI in the United States
  • 10.4.3. Gender-specific Incident Cases of AMI in the United States
• 10.5. EU4 and the UK
  • 10.5.1. Total Incident Cases of AMI in EU4 and the UK
  • 10.5.2. Type-specific Incident Cases of AMI in EU4 and the UK
  • 10.5.3. Gender-specific Incident Cases of AMI in EU4 and the UK
• 10.6. Japan
  • 10.6.1. Total Incident Cases of AMI in Japan
  • 10.6.2. Type-specific Incident Cases of AMI in Japan
  • 10.6.3. Gender-specific Incident Cases of AMI in Japan

11. Patient Journey

12. Marketed Drugs

• 12.1. Key Cross Competition
• 12.2. TNKASE (tenecteplase): Genentech
  • 12.2.1. Product Description
  • 12.2.2. Regulatory Milestones
  • 12.2.3. Safety and Efficacy
• 12.3. REPATHA (evolocumab): Amgen
  • 12.3.1. Product Description
  • 12.3.2. Regulatory Milestones
  • 12.3.3. Clinical Developmental
  • 12.3.4. Safety and Efficacy
• 12.4. ZONTIVITY (vorapaxar): Merck
  • 12.4.1. Product Description
  • 12.4.2. Regulatory Milestones
  • 12.4.3. Other Developmental Activity
  • 12.4.4. Clinical Development
  • 12.4.5. Safety and Efficacy
• 12.5. PRALUENT (alirocumab): Regeneron/Sanofi
  • 12.5.1. Product Description
  • 12.5.2. Regulatory Milestones
  • 12.5.3. Other Developmental Activities
  • 12.5.4. Clinical Development
  • 12.5.5. Safety and Efficacy

13. Other Marketed Assets

• 13.1. Key Cross Competitors
• 13.2. INSPRA (eplerenone): Pfizer
  • 13.2.1. Product description
  • 13.2.2. Mechanism of action
  • 13.2.3. Regulatory milestones
  • 13.2.4. Safety and efficacy
• 13.3. PLAVIX (clopidogrel bisulfate): Sanofi-Aventis/Bristol-Myers Squibb
  • 13.3.1. Product description
  • 13.3.2. Mechanism of action
  • 13.3.3. Regulatory milestones
  • 13.3.4. Other developmental activities
  • 13.3.5. Safety and efficacy
• 13.4. BRILINTA/BRILIQUE (ticagrelor): AstraZeneca
  • 13.4.1. Product description
  • 13.4.2. Mechanism of action
  • 13.4.3. Regulatory milestones
  • 13.4.4. Safety and efficacy
• 13.5. EFFIENT/EFIENT (prasugrel): Daiichi Sankyo/Eli Lilly and Company
  • 13.5.1. Product description
  • 13.5.2. Mechanism of action
  • 13.5.3. Regulatory milestones
  • 13.5.4. Other development activity
  • 13.5.5. Safety and efficacy
• 13.6. ATACAND (candesartan): AstraZeneca/Takeda
  • 13.6.1. Product description
  • 13.6.2. Mechanism of action
  • 13.6.3. Regulatory milestones
• 13.7. DIOVAN (valsartan): Novartis
  • 13.7.1. Product description
  • 13.7.2. Mechanism of action
  • 13.7.3. Regulatory milestones
  • 13.7.4. Safety and efficacy

14. Emerging Therapies

• 14.1. Key Cross Competition
• 14.2. JARDIANCE (empagliflozin): Boehringer Ingelheim/Eli Lilly and Company
  • 14.2.1. Product Description
  • 14.2.2. Other Developmental Activities
  • 14.2.3. Clinical Development
• 14.3. Selatogrel: Idorsia Pharmaceuticals
  • 14.3.1. Product Description
  • 14.3.2. Other Developmental Activities
  • 14.3.3. Clinical Development
  • 14.3.4. Safety and Efficacy
• 14.4. Dutogliptin: Recardio
  • 14.4.1. Product Description
  • 14.4.2. Other Developmental Activities
  • 14.4.3. Clinical Development
  • 14.4.4. Safety and efficacy
• 14.5. Milvexian: Janssen Pharmaceutical/Bristol Myers Squibb
  • 14.5.1. Product Description
  • 14.5.2. Other Developmental Activities
  • 14.5.3. Clinical Development
• 14.6. FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
  • 14.6.1. Product Description
  • 14.6.2. Other Developmental Activities
  • 14.6.3. Clinical Development
  • 14.6.4. Safety and efficacy
• 14.7. FDY-5301: Faraday Pharmaceuticals
  • 14.7.1. Product Description
  • 14.7.2. Other Developmental Activity
  • 14.7.3. Clinical Development
  • 14.7.4. Safety and Efficacy
• 14.8. CSL112: CSL Behring
  • 14.8.1. Product Description
  • 14.8.2. Clinical Development
  • 14.8.3. Safety and Efficacy
• 14.9. Olpasiran: Amgen
  • 14.9.1. Product Description
  • 14.9.2. Other Developmental Activities
  • 14.9.3. Clinical Development
  • 14.9.4. Safety and Efficacy

15. Acute Myocardial infarction (AMI): 7MM Market Analysis

• 15.1. Key Findings
• 15.2. Market Outlook
• 15.3. Conjoint Analysis
• 15.4. Key Market Forecast Assumptions
• 15.5. Total Market Size of AMI in the 7MM
• 15.6. United States Market Size
  • 15.6.1. Total Market Size of AMI in the United States
  • 15.6.2. Market Size of AMI by Therapies in United States
• 15.7. EU4 and the UK Market Size
  • 15.7.1. Total Market Size of AMI in EU4 and the UK
  • 15.7.2. Market Size of AMI by Therapies in EU4 and the UK
• 15.8. Japan Market Size
  • 15.8.1. Total Market Size of AMI in Japan
  • 15.8.2. Market Size of AMI by Therapies in Japan

16. Unmet Needs

17. SWOT Analysis

18. KOL Views

19. Market Access and Reimbursement

• 19.1. United States
  • 19.1.1. Centre for Medicare and Medicaid Services (CMS)
• 19.2. EU4 and the UK
  • 19.2.1. Germany
  • 19.2.2. France
  • 19.2.3. Italy
  • 19.2.4. Spain
  • 19.2.5. United Kingdom
• 19.3. Japan
  • 19.3.1. MHLW
• 19.4. Reimbursement Scenario and Key HTA Decisions in AMI

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight